Selection and characterization of a human ovarian cancer cell line resistant to auranofin

Ida Landini1, Andrea Lapucci1, Alessandro Pratesi2, Lara Massai3, Cristina Napoli3, Gabriele Perrone1, Pamela Pinzani4, Luigi Messori2,*, Enrico Mini1,* and Stefania Nobili3,*

1Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
2Department of Chemistry "Ugo Schiff", University of Florence, Firenze, Italy
3Department of Health Sciences, University of Florence, Firenze, Italy
4Department of Experimental and Clinical Biomedical Sciences, University of Florence, Firenze, Italy

*These authors have contributed equally to this work

Correspondence to: Enrico Mini, email: enrico.mini@unifi.it
Stefania Nobili, email: stefania.nobili@unifi.it
Luigi Messori, email: luigi.messori@unifi.it

Keywords: auranofin; tumour drug resistance; human tumour cell lines; drug effects; gene expression

ABSTRACT

The anti-arthritic drug auranofin exerts also potent antitumour activity in in vitro and in vivo models, whose mechanisms are not yet well defined. From an auranofin-sensitive human ovarian cancer cell line A2780, a highly resistant (>20-fold) subline (A2780/AF-R) was developed and characterized. Marked reduction of gold accumulation occurred in auranofin-resistant A2780 cells. Also, moderately higher thioredoxin reductase activity in A2780/AF-R cells was observed while no changes in intracellular glutathione content occurred. Resistance to auranofin was associated with a low level of cross-resistance to some investigational gold compounds as well as to oxaliplatin and other anticancer drugs with different mode of action (i.e. melphalan, vinblastine, doxorubicin, etoposide, and paclitaxel). Reduced gold accumulation was associated to substantial gene expression changes in various influx (e.g. SLC22A1, SLC47A1, SLCO1B1) and efflux (e.g. ABCB1, ABCC2, ABCC3) transporters. The expression levels of selected proteins (i.e. SLC22A1, SLC47A1, P-gp) were also changed accordingly. These data provide evidence that multiple drug transporters may act as mediators of transport of auranofin and other gold compounds in cancer cells. Further investigation into the molecular mechanisms mediating transport of auranofin and new gold complexes in view of their potential clinical application in the treatment of cancer is warranted.

INTRODUCTION

Auranofin, an oral gold (I) compound, was developed in the 1980’s for the treatment of rheumatoid arthritis [1]. Despite its appreciable efficacy in the treatment of this disease, auranofin is at present rarely used in the clinic since novel and more effective anti-rheumatic drugs have become available [2, 3]. Yet, auranofin in recent years has shown promise in the treatment of several different diseases, including cancer. Preclinical evidence in various tumour models [4-7] have contributed to the implementation of clinical trials of auranofin in different types of tumours (e.g. leukaemia, ovarian cancer and other solid tumours) [8]. Most of these studies are based on programs of drug repurposing promoted by the National Institute of Health (NIH) [9] and other institutions [10, 11].
It is now ascertained that auranofin exerts potent antineoplastic activity in various in vitro and in vivo tumour models [12-14]. It also represents a reference compound when new gold-based compounds are studied as potential anticancer drugs.

The mechanism of action of auranofin in cancer is not fully understood. Auranofin was shown to cause a dose-dependent inhibition on DNA, RNA and protein synthesis in human tumour Hela cells and murine B16 tumour cells at cytotoxic concentrations [4, 5]. However, subsequent studies investigating the role of DNA replicative enzymes failed to show that the inhibition of DNA replication is a critical factor in the cytotoxicity of this agent [15]. Thus, it was recognized that auranofin may interact with several other cellular macromolecules leading to injures to diverse cell structures and inhibition of a number of essential signalling pathways involved in the progression of cancer [12, 16]. However, unlike cisplatin, extensive evidence showed that cytotoxicity of auranofin is not due to a direct interaction with DNA [17].

The antineoplastic activity of auranofin relies on inhibition of cell proliferation by induction of apoptotic cell death and block of tumour neoangiogenesis [12, 13]. Auranofin was shown to induce apoptosis in several different cancer cell lines through increased production of reactive oxygen species and by modification of cell redox status [18, 19]. In addition, as other gold compounds, auranofin inhibits mitochondrial [20] and cytosolic [21] thioredoxin reductase leading to oxidative stress including peroxiredoxin 3 oxidation [18], and consequent cellular accumulation of H₂O₂ which triggers Bax-Bak-dependent apoptosis [18, 22]. A further consequence of thioredoxin reductase inhibition is the disruption of selenoprotein synthesis that leads to the disruption of DNA synthesis [23].

Also, auranofin inhibits several tumour signalling pathways, independent pro-inflammatory and neoangiogenesis pathways, contributing to the control of cancer growth and progression [13]. As several other gold compounds, it has been suggested that auranofin targets the proteasome [12]. Notably, in tumour cells, auranofin does not inhibit the three main catalytic peptidase activities of purified 20S proteasome [24] but inhibits 19S proteasome-associated deubiquitinases, consequently inducing cell apoptosis [25, 26]. Overall, these observations suggest for auranofin a complex and multifactorial mode of action.

To further improve the understanding of the molecular mechanisms of auranofin cytotoxicity as well as to unravel the mechanisms responsible for resistance to gold compounds, the development and characterization of auranofin-resistant cell lines may be useful. Very few studies have so far addressed these issues [27, 28] and none of them were accomplished in human tumour cell lines. Indeed, experimental studies using relevant in vitro and in vivo models of drug-resistance and drug-sensitive human cancer may lead to improved knowledge of the mechanisms of action and resistance of gold compounds as well as of the strategies to develop gold-based analogues of potential clinical utility.

We describe here the development and characterization of an auranofin-resistant human ovarian cancer cell line (A2780/AF-R) which was established from an auranofin-sensitive parental cell line (A2780). Properties of this resistant line were compared with those of the parental line. Resistance to auranofin and cross-resistance to several other drugs including recently synthesized gold (I) and (III) compounds, were determined. Furthermore, in these cell lines, we examined differences in cellular gold content and in the expression of proteins potentially involved in cell influx/efflux of auranofin as well as the potential reversion of auranofin resistance by verapamil.

RESULTS

Characteristics of the auranofin resistant cell line

Parental A2780 cells were cultured in the continuous presence of stepwise increasing auranofin concentrations. Following a six-step rise of auranofin concentrations from 0.1 to 7.0 μM in 8 months, a resistant subline was obtained (A2780/AF-R). At this stage, a resistance index (RI) of about 22-fold was obtained and the selected cells were able to grow at 7 μM auranofin, a concentration at which no cells of the parental line survive. In monolayer culture the A2780/AF-R cell line had a doubling time similar to that of the parental A2780 cell line (22.60 ± 2.58 and 19.70 ± 4.66 hours, respectively). Periodic IC₅₀ determinations showed that the degree of auranofin resistance in the A2780/AF-R cell line was stable, during a 3-month period of subculture in drug-free medium (RI 20.7, 18.0 and 18.7 at 1, 2 and 3 months, respectively).

Cross-resistance studies

An analysis of the pattern of sensitivity/resistance to other gold (I or III)-based compounds of more recent synthesis (Auo6x6, AuPhen₂, Aubipy, AuL12, Au(NHC)Cl and Au(NHC)₃) (Figure 1) was performed by concurrent comparisons of drug IC₅₀ values of the auranofin resistant A2780 subline (A2780/AF-R) with those of the parental auranofin sensitive A2780 cell line. Only AuPhen₂ was more active, on a micromolar basis, than auranofin. In the sensitive cell line the relative degree of cytotoxicity was AuPhen₂>auranofin>Au(NHC)₃, Au(NHC)Cl>Auoxo6> Aubipy,>AuL12 (most to least active) (Figure 2A).

The development of primary resistance to auranofin in vitro also resulted in a low level of cross-resistance to three of the tested gold compounds (Aubipy, AuPhen₂, and Au(NHC)Cl, cross-resistance index (CRI) of 2.5, 3.6 and 2.7, respectively) but not to other three gold-compounds (Auoxo6, AuL12, and Au(NHC)₃) after a 72-hour exposure.
The latter compounds were able to completely circumvent resistance to auranofin (CRI <1.5) (Figure 2A).

Cross-resistance to other drugs commonly used in ovarian cancer therapy was assessed by concurrent comparisons of the IC_{50} values of the resistant subline with those of the parental line. Cross-resistance to these drugs variably accompanied development of *in vitro* primary resistance to auranofin in this line. The A2780/AF-R subline was modestly cross-resistant to oxaliplatin, melphalan, etoposide, vinblastine, doxorubicin and paclitaxel (CRI from 3.9 to 2.1, respectively). No cross-resistance to cisplatin, carboplatin and docetaxel was demonstrated (CRI≤1.5) (Figure 2B).

**Cellular gold accumulation**

To investigate whether resistance to auranofin in A2780/AF-R was related to a decrease in drug accumulation, cellular gold content was determined during an 8-hour exposure to 10 μM auranofin in both A2780/AF-R and A2780 (Figure 3). When auranofin cellular accumulation was examined, a substantial reduction in the content and in the AUC of gold was found in A2780/AF-R cells compared to that in A2780 sensitive cells (338.0 pmol/10^6 cells vs 4630.0 pmol/10^6 cells at 480 min, respectively, i.e. an 86.3% reduction; AUC, 1.3x10^3 vs 3.5x10^4 pmol x hr/10^6 cells, respectively, i.e. a 96.3% reduction). The accumulation of cellular gold was rapid and reached a plateau at about 120 min in A2780 cells. In contrast, the accumulation of cellular gold was dismal and displayed a linear kinetics during the entire drug exposure time in A2780/AF-R cells.

**mRNA expression levels of transport and trafficking pathway genes in A2780/AF-R and A2780**

To verify whether changes in the expression of transport and trafficking pathway genes might be associated to the observed reduced gold accumulation in auranofin resistant cells, mRNA expression levels of candidate genes were measured in A2780/AF-R and A2780 cells. Overall, changes in mRNA expression of 13 out of 24 evaluated genes in A2780/AF-R cells compared to A2780 cells were observed. Seven were up-regulated (from 3.3 to >2x10^6-folds) and 6 down-regulated genes (from 3.4 to 1.4x10^3-folds) (Figure 4, Table 1).

Among genes belonging to the solute carrier family (SLC), a 21.9-fold decrease and a 1.2x10^3-fold increase of mRNA levels of the organic cation transporter genes SLC22A1 and SLC22A3, respectively, was observed in A2780/AF-R cells compared to the A2780 cells. Also, a 6.3-fold increase in the mRNA expression of the copper transporter protein SLC31A2 was observed in A2780/AF-R cells compared to A2780 cells and a 1.4x10^3-fold decrease of mRNA level of the multidrug/toxin extrusion transporter SLC47A1 was observed in A2780/AF-R. No significant changes were observed in the other 3 solute carrier family genes analysed.

A substantial increase in mRNA expression levels of the ATP binding cassette transporters ABCB1, ABCC2 and ABCC3 (from 48 to >1x10^6 folds) was observed in the resistant cell line compared with the sensitive one whereas a decrease of about 11-fold was observed in the mRNA of ABCG2 in the auranofin resistant cell line. The highest

![Figure 1: Chemical structures of gold (I) and gold (III) compounds.](image-url)
increase was observed in ABCC3, as a consequence of its almost undetectable expression level in A2780 cells.

No substantial difference was observed between the expression of the copper transporters ATP7A and ATP7B or the Na⁺/K⁺ ATPase transporters ATP1A1 and ATP1A2 between the two cell lines with the exception of a 11.6-fold decrease in mRNA expression levels of ATP1A3 in the resistant cell line compared with the sensitive one. No mRNA expression difference was observed for ATOX1.

Among CLT genes that mediate endocytosis, an about 3-fold increase in CLTB and CLTD gene expression was observed in the auranofin resistant cell line. An about 3-fold decrease was observed in PIK3CA expression in A2780/AF-R cells as compared to A2780 cells.

**Protein levels of selected relevant transporters**

To determine whether the observed variations in mRNA levels of selected relevant transporters were correlated with variations at protein levels, Western blotting analysis of SLC22A1, SLC47A1 and P-gp was performed in A2780 and A2780/AF-R cells. Although less markedly,

---

*Figure 2: Comparative cytotoxicity of auranofin and other gold compounds (A) and classical chemotherapeutic agents (B) on cell growth of A2780 and A2780/AF-R cells. Data are means ± standard error derived from at least three independent 72-h drug exposure experiments. CRI, cross-resistance index; *p<0.001; **p<0.05.*
results confirmed mRNA observations. Downregulation of SLC22A1 and SLC47A1 proteins in A2780/AF-R compared with A2780 cells was observed. P-gp expression was negligible in A2780 sensitive cells but was detectable at low levels in A2780/AF-R cells (Figure 5).

Reversal of auranofin resistance by verapamil

Verapamil abrogates efflux of anticancer drugs mediated by P-glycoprotein (P-gp) by competitive inhibition of drug transport. Since the A2780/AF-R displayed characteristics of drug accumulation compatible with the classical multi-drug resistance phenotype mediated by the overexpression of P-gp and other ABC transporters, verapamil was used to investigate its ability to reverse auranofin resistance in vitro. Results showed that verapamil partially reverted the resistant phenotype. In A2780/AF-R, co-exposure of auranofin with verapamil 5, 10, 20 μM resulted in a 2.7-, 2.9- and 4.8-fold increase in the cytotoxicity of auranofin, respectively (Figure 6). No substantial differences in the growth inhibitory effects of auranofin were observed after co-exposure with verapamil in the auranofin sensitive cell line (i.e. 1.2-fold cytotoxicity increase following the addition of verapamil 5, 10, 20 μM) (Figure 6).

Activity of thioredoxin reductase

To evaluate a potential role of thioredoxin reductase (TrxR) in the acquired resistance to auranofin, its activity was investigated in both cell lines. Results showed that cellular TrxR activity was moderately higher in A2780/AF-R cells compared with A2780 cells (1.8-fold variation) (Table 2).

Intracellular glutathione levels

To investigate whether putative increased intracellular glutathione levels may contribute to the development of resistance to auranofin, basal total and reduced glutathione was evaluated in the auranofin sensitive and resistant cell lines. No difference was observed in total and reduced intracellular glutathione levels in A2780/AF-R compared to A2780 cells (Table 3). These results do not show correlation between glutathione and auranofin resistance in A2780/AF-R cells characterized by a high transport deficit.

DISCUSSION AND CONCLUSIONS

The development of resistance to anticancer agents is the main determinant of failure of anticancer chemotherapy in initially drug sensitive cancers [29]. In vitro human cell lines resistant to anticancer drugs represent useful models to study the mechanisms of drug action and tumour resistance. This is the first investigation describing a human tumour cell line with acquired resistance to a gold compound.

The human ovarian A2780 cell line, intrinsically sensitive to cisplatin, was used to develop an auranofin resistant cell line. Following stepwise selection with auranofin, an about 22-fold resistant subline (A2780/AF-R) was obtained. Auranofin is currently undergoing clinical trial investigations in various types of cancers including ovarian cancer [10]. It also represents a reference compound when pharmacology of gold-based compounds is investigated.

The cytotoxic activity of a series of gold (I) and gold (III) compounds, platinum compounds and other cytotoxic anticancer agents characterized by different mechanisms of action against auranofin-resistant A2780/AF-R cells was tested. Resistance to auranofin in the A2780/AF-R cell line was associated with a low level of cross-resistance to three of the gold compounds tested (i.e. Aubipy, Au2Phen2, and Au(NHC)Cl) as well as to oxaliplatin,
Figure 4: Up- and down-regulated genes in A2780/AF-R compared with A2780 cells. Relative mRNA expression levels of study genes according to 18S mRNA in A2780 (white bars) and A2780/AF-R (black bars). >3-fold up or down-regulation of A2780/AF-R compared with A2780.
melphalan, doxorubicin, etoposide, vinblastine, and paclitaxel. Lack of cross-resistance was observed against the other gold compounds and anticancer agents tested.

Knowledge of the cellular pharmacology of auranofin in experimental tumour models is still limited and little information is available on the mechanisms of tumour resistance to gold compounds [16]. The cytotoxic effects of auranofin appear to be directly related with the cellular content of auranofin-derived gold [5]. Also, in cultured human normal HE epithelial cells following stepwise selection for resistance to auranofin it was shown that maintenance of gold concentrations at a low level was a mechanism contributing to the observed cellular acquired resistance to auranofin [27]. Our data showed that intracellular gold accumulation during an 8-hour drug exposure time was markedly reduced in A2780/AF-R cells as compared to A2780 cells. This strongly suggests that the reduced sensitivity to auranofin is primarily due to a reduced steady-state cellular content of auranofin.

At present, only limited information is available on the mechanisms of intracellular uptake and accumulation of gold compounds [30]. Due to the ability of gold compounds to interact with thiol groups, transport through a thiol-shuttle has been suggested also involving reversible binding to serum albumin [31]. More recently, processes potentially involved in intracellular metal accumulation [32].

Our analysis of mRNA expression of genes potentially involved in cell transport or trafficking of gold compounds showed variations in 13 out of 24 genes in A2780/AF-R cells compared with A2780 cells. Seven genes were up-regulated and 6 genes were down-regulated. It is known that the physiological role of members of the SLC family is heterogeneous since some of them are involved in the influx or efflux of organic cations or anions or in both these processes [35]. The organic cation transporters OCT1 and OCT2 (encoded by SLC22A1 and SLC22A2, respectively) play an important role in the cellular uptake of some gold (I) N-heterocyclic carbene complexes (e.g. chlorido-[1,3-dimethyl-4,5-diaryl-2-ylidene] gold complexes) [32].

We observed a downregulation of SLC22A1 both at mRNA and protein expression level in A2780/AF-R cells

| Gene name  | Description                                                        | Fold change |
|------------|--------------------------------------------------------------------|-------------|
| Up-regulated genes |                                                                 |             |
| ABCC3      | ATP binding cassette subfamily C member 3                          | 2.1 \times 10^6 |
| ABCB1      | ATP binding cassette subfamily B member 1                          | 5.2 \times 10^3 |
| SLC22A3    | Solute carrier family 22 member 3                                  | 1.2 \times 10^1 |
| ABCC2      | ATP binding cassette subfamily C member 2                          | 48.0        |
| SLC31A2    | Solute carrier family 31 member 2                                  | 6.3         |
| CLTD       | Clathrin, heavy chain-like 1                                        | 3.4         |
| CLTB       | Clathrin, light chain B                                             | 3.3         |
| Down-regulated genes |                                                             |             |
| SLC47A1    | Solute carrier family 47 member 1                                 | 1.4 \times 10^3 |
| SLC22A1    | Solute carrier family 22 member 1                                  | 21.9        |
| ATP1A3     | ATPase, Na+/K+ transporting, alpha 3                               | 11.6        |
| ABCG2      | ATP-binding cassette, sub-family G member 2                        | 11.2        |
| SLCO1B1    | Solute carrier organic anion transporter family member 1B1         | 4.1         |
| PIK3CA     | Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha | 3.4         |
Table 2: Basal thioredoxin reductase activity in A2780 and A2780/AF-R cells

| Cell lines      | TrxR activity (unit/mg protein x min ± SD) | n   |
|-----------------|------------------------------------------|-----|
| A2780           | 2.751±0.665                              | 3   |
| A2780/AF-R      | 4.916±1.537                              | 3   |

TrxR, thioredoxin reductase; SD, standard deviation; n, number of independent experiments

Figure 5: Variation of protein expression levels of selected transporters. Protein levels of SLC22A1, SLC47A1 and P-gp were determined by Western blotting. β-actin was included as a loading control.

Figure 6: Modulation of P-glycoprotein-mediated resistance in A2780/AF-R and A2780 by verapamil. Dose-response curves for auranofin (from 0.1 to 100 μM with or without verapamil (5, 10 or 20 μM) in A2780 (solid curves) and A2780/AF-R (dashed curves) cells are shown. Open or solid circles, 0 μM verapamil; open or solid squares, 5 μM verapamil; open or solid up triangles, 10 μM verapamil; open or solid down triangles, 20 μM verapamil. Data are means ± standard error derived from three independent 72-h drug incubation experiments.
Table 3: Basal intracellular glutathione levels in A2780 and A2780/AF-R cells

| Cell lines | GSH + GSSG μg/10^6 cells ± SD | GSH μg/10^6 cells ± SD |
|------------|-------------------------------|------------------------|
| A2780      | 17.12±2.02                    | 14.51±1.51             |
| n          | 3                             | 3                      |
| A2780/AF-R | 17.76±2.08                    | 15.39±1.53             |
| n          | 3                             | 3                      |

GSH + GSSG, total glutathione; GSH, reduced glutathione; SD, standard deviation; n, number of independent experiments

compared to A2780 cells. These findings suggest that OCT1 (SLC22A1) may contribute to the uptake of auranofin and to resistance to this drug. In addition, it has been shown that oxaliplatin is an excellent substrate for OCT1 [36]. Thus, overexpression of SLC22A1 could explain at least in part the observed cross-resistance to this drug in A2780/AF-R cells. While SLC22A2 mRNA expression was unchanged, the expression of SLC22A3 gene, encoding for OCT3, was higher in A2780/AF-R cells compared with A2780 cells. It has been suggested that oxaliplatin is transported by OCT3 [37] and that this transporter contributes to accumulation of this drug into cancer cells [38]. However, it has also been shown that intracellular accumulation of oxaliplatin is mainly due to increased expression of OCT2 rather than OCT3 or other OCTs as it occurs for other platinum compounds [39]. No information is available on the role of OCT3 in the transport of gold compounds or other anticancer drugs. Our results do not support a role of OCT3 in the resistance to auranofin.

The copper transporter CTR1, codified by SLC31A1, has also been suggested to be involved in the uptake and accumulation of gold (I) N-heterocyclic carbene complexes [32]. The expression of SLC31A1 was found slightly downregulated (2.9-fold) in A2780/AF-R cells compared to A2780 cells. This could be related to the reduced gold accumulation and cytotoxicity of auranofin observed in A2780/AF-R cells. The role of CTR2 in the uptake and accumulation of gold compounds is currently unknown. A modest upregulation of SLC31A2 gene expression in A2780/AF-R cells compared to A2780 cells was observed. The contribution of this gene up-regulation to the accumulation and cytotoxicity of auranofin remains undefined.

Cisplatin and carboplatin [33, 40] and to a lesser extent oxaliplatin [41] are substrate of CTR1. Cisplatin and carboplatin are also substrates of CTR2. No clear correlation between observed CTR1 and CTR2 expression levels and sensitivity/resistance patterns to platinum compounds tested can be established.

MATE transporters are responsible for the excretion of xenobiotic organic cations in the kidney and liver. MATE1 encoded by SLC47A1 is also expressed in other tissues and is involved in the renal accumulation and nephrotoxicity of platinum agents [42]. The expression of SLC47A1 gene and that of its transcript was downregulated in A2780/AF-R cells compared with A2780 cells. This data may explain the reduced cytotoxicity of oxaliplatin in A2780/AF-R cells and suggests a potential role of MATE1 also in auranofin transport and resistance.

Organic anion transporting polypeptides (OATPs) belonging to the SLCO subfamily play a relevant role in transporting endo- and xenobiotics, including several anticancer drugs, across plasma membranes. SLCO1B3 gene overexpression was associated with increased cellular accumulation of platinum and increased sensitivity to platinum anticancer drugs in human tumour cell lines [43]. No difference in the expression of SLCO1B3 in A2780/AF-R cells compared with A2780 cells was observed. A decrease in the expression of SLCO1B1 in A2780/AF-R cells compared with A2780 cells was instead shown. Although the role of SLCO1B1 in the transport of metal compounds has not been investigated, a contribution of downregulation of this carrier to tumour resistance to auranofin and oxaliplatin in A2780 cells cannot be ruled out.

ATP binding cassette transporters are members of a large family of cell membrane efflux transporters. Overexpression of these transporters confers resistance to a large series of structurally unrelated anticancer drugs [44].

P-gp, codified by the ABCC1 gene, is responsible for the development of the multidrug resistance cancer phenotype [45, 46]. Increased ABCC1 mRNA expression level in A2780/AF-R cells as compared to A2780 cells was observed. This was confirmed also at the protein level. Auranofin sensitivity was partially restored after co-exposure of the resistant cell line to verapamil and auranofin. These findings suggest a contribution of this transporter in the efflux of auranofin and in the development of acquired resistance to this drug. Little information is available on the role of P-gp in the cellular kinetics and activity of gold compounds. A recent published study showed that an investigational carbene gold compound was active in two human leukemia sublines resistant to either vincristine or daunorubicin, due to overexpression of P-gp [47]. No difference in the gold uptake between these resistant leukaemia cell lines and their sensitive counterpart was observed, conveying that the study gold compound was not a P-gp substrate [47].
These data suggest that different gold compounds may undergo different mechanisms of drug efflux.

Since \textit{ABCB1} overexpression is involved in tumour resistance to several anticancer drugs including vinca alkaloids, doxorubicin, etoposide and taxanes, low grade cross-resistance to some of these drugs observed in A2780/AF-R cells might be mediated by increased P-gp levels.

Similar considerations may be done for cross-resistance to oxaliplatin and melphalan observed in A2780/AF-R cells. In colon cancer cell lines the overexpression of \textit{ABCB1} was associated to oxaliplatin resistance [48]. Also, increased \textit{ABCB1} expression and decreased intracellular melphalan accumulation as well as increased resistance to this drug in a human HL-60 promyelocytic leukaemia cell line have been reported [49].

We observed an increase in the mRNA expression of \textit{ABCC2}, a member of the MRP subfamily, in A2780/AF-R cells as compared to A2780 cells. In tumour models the overexpression of this transporter has been associated with the development of tumour resistance to several anticancer agents including platinum compounds, vinblastine and etoposide [50]. In keeping with these data, resistance to these drugs was observed in A2780/AF-R cells. A high level of \textit{ABCC3} expression was observed in A2780/AF-R cells as compared to A2780 due to the negligible expression of this gene in A2780 cells. Resistance to etoposide has been associated to \textit{ABCC3} overexpression [51], thus resistance to this drug in A2780/AF-R cells may be in part due to this occurrence.

Our association data suggest a role of these ATP binding cassette transporters also in the development of acquired resistance to auranofin.

Breast cancer resistance protein (BCRP) encoded by \textit{ABCG2} displays an important role in resistance to several anticancer drugs, including camptothecins, antifolates and anthracyclines. We observed down-regulation of \textit{ABCG2} in A2780/AF-R cells compared to A2780 cells but no meaningful association could be established with observed sensitivity/resistance patterns. The involvement of BCRP in the transport of platinum and other metal drugs has in fact been not ascertained. In particular, contradictory results have been reported on the role of this transporter in the development of oxaliplatin resistance.

Following uptake by CTRs, intracellular copper and other metals are tightly controlled and shuttled through subcellular compartments via interactions with copper chaperones and secreted. Homeostasis of copper is maintained by antioxidant 1 (ATOX1) that transfers copper to the copper transporting P1B-type ATPases ATP7A and ATP7B. It has been shown that overexpression of ATOX1, ATP7A and ATP7B reduces cisplatin accumulation and sensitivity [52-54]. No substantial differences in the mRNA expression of these genes were observed in A2780/AF-R cells compared to the A2780 cells and no association with resistance to auranofin was ascertained.

\textit{ATP1A1}, \textit{ATP1A2} and \textit{ATP1A3} genes encode for isoforms of Na\(^+\)/K\(^+\)-ATPase, a membrane protein responsible the electrochemical Na\(^+\)/K\(^+\) gradients essential for Na\(^+\)-coupled transport of various organic and inorganic molecules. We observed downregulation of \textit{ATP1A3} gene expression and no significant change in the mRNA expression of \textit{ATP1A1} and \textit{ATP1A2} genes in A2780/AF-R cells compared to A2780 cells. Very limited data are available on the involvement of these proteins in the transport of anticancer agents including metal drugs. However, it has been shown that inhibition of Na\(^+\)/K\(^+\)-ATPase with ouabain reduces platinum accumulation in A2780 cells and that lower expression of Na\(^+\)/K\(^+\)-ATPase alpha-1 subunit is associated with resistance to cisplatin [55]. Our results do not allow to speculate on the potential role of these proteins in the resistance to auranofin and other drugs tested.

To verify the hypothesis that selective inhibition of clathrin function reduces cytotoxic activity of gold compounds as a consequence of reduced gold uptake through clathrin-mediated endocytosis [32], we investigated the potential association of the expression of clathrins A (\textit{CLTA}), B (\textit{CLTB}), C (\textit{CLTC}) and D (\textit{CLTD}) with auranofin resistance. The observed modest increase of \textit{CLTB} and \textit{CLTD} expression levels in the auranofin resistant cell line compared with the auranofin sensitive cell line do not support the hypothesis that gold uptake may be mediated by clathrin endocytosis.

It was also shown that a modest attenuation of the cytotoxicity of some gold carbene complexes occurred upon addition of wortmannin, a fungal metabolite inhibitor of PIK3CA [32]. Since activated PIK3CA is involved in the signalling cascade leading to macropinosome formation, it was speculated that this finding may be due to specific inhibition of this putative mechanism of gold compound uptake. However, no information is available on its role in the transport of anticancer agents with the exception of macromolecular conjugated drugs. Also, PIK3CA is not only involved in intracellular trafficking but also in several other processes including cell growth, proliferation, differentiation, motility and survival. The mRNA expression of \textit{PIK3CA} was modestly decreased in A2780/AF-R cells compared to A2780 cells. This borderline association does not allow us to conclude that macropinocytosis play a role in the uptake of gold compounds.

Due to the recognized ability of auranofin to inhibit TrxR, we verified if alterations in TrxR enzymatic activity may contribute to the mechanism of acquired resistance to auranofin. The moderately higher activity (< 2-fold) observed in the A2780/AF-R cells compared with A2780 cells might reflect a concurrent adaptative cellular response to stepwise selection with increasing auranofin concentrations during time, while high level resistance developed due to transport defects. In vitro tumour sensitivity and resistance to auranofin and platinum compounds have been associated to changes in intracellular
TrxR activity. High level (≥ 10-fold) intrinsic resistance to auranofin has been associated to a substantial increase in TrxR activity in non-small cell lung cancer cell lines [56]. Also, low-intermediate level acquired resistance (about 2-5-fold) to cisplatin associated to slight-moderate increases (1.3-2-fold) in TrxR activity have been reported in various tumour cell lines [57-59]. No cross-resistance with cisplatin was however observed in our model. It is conceivable that this mechanism may have contributed at least in part to auranofin resistance observed in A2780/AF-R cells.

Thiols may play an important role in the molecular mechanisms of resistance to anticancer drugs, including metal drugs. Glutathione is the main cellular thiol that interacts with copper and platinum-based drugs. It is common to find elevated glutathione levels in cisplatin resistant tumour models [60]. No differences in intracellular glutathione content between A2780/AF-R cells and A2780 cells were observed. Thus, no contribution of this mechanism of resistance was noted.

Our results support the knowledge that transport of auranofin is a critical determinant of cytotoxicity of this drug in cancer cells. An about complete abolition (>95%) of gold accumulation occurred in A2780/AF-R cells. This was associated to a high level (>20 fold) of acquired resistance. The only previously reported data do not relate to a tumour model (HE cells) [27]. In this study, the HE auranofin-resistant subline was selected by a stepwise process similar to that used in the present investigation, reaching a somewhat lower drug concentration (2 μM). Following a 24-h auranofin exposure, cellular gold content observed in auranofin-resistant HE cells were only one-half of those observed in parental HE cells.

The observed highly reduced accumulation of gold in A2780/AF-R cells was associated to expression changes of various influx and efflux transporters. In addition, verapamil reverted only partially resistance to auranofin at concentrations able to abrogate almost completely vinblastine and doxorubicin resistance in the classical multidrug resistance phenotype. This provides evidence that multiple drug transporters may act as mediators of auranofin and possibly of other gold compound transport in cancer cells. However, the relative contribution of the single transporters investigated in this study remains to be settled by future studies. An additional contribution to the degree of auranofin resistance by the observed moderately increased TrxR activity may not be ruled out.

Our findings warrant further investigation into the molecular mechanisms mediating transport of auranofin in view of a potential role of this agent in the treatment of human cancer. The understanding of gold transportome by means of transcriptomics analysis is ongoing at our laboratory as well as the attempt to evaluate the relative contribution of single processes potentially involved by functional studies with specific transport inhibitors or gene silencing of transporters and protein expression studies. This will provide crucial insights into the cellular pharmacology of auranofin and information useful for the design of new gold complexes for clinical application.

**MATERIALS AND METHODS**

**Drugs and supplies**

Auranofin was obtained from Vinci Biochem (Vinci, Italy); Auoxo6 [61] and Au_Phen [62], two dinuclear gold (III) compounds, and Aubipy [63], an organogold (III) complex, were provided by Prof. M.A. Cinellu. AuL12 [64], a gold (III) dithiocarbamate complex, was provided by Prof. D. Fregona. The two gold (I) carbene compounds, namely chlorido (1-butyl-3-methyl-imidazole-2-ylidene) gold (I) (Au(NHC)Cl) and bis(1-butyl-3-methyl-imidazole-2-ylidene) gold (I) (Au(NHC)2) [65], were provided by Prof. C. Gabbiani. Cisplatin, oxaliplatin, carboplatin, melphalan, vinblastine, etoposide, doxorubicin, paclitaxel, docetaxel, verapamil and sulforhodamine B (SRB) were obtained from Sigma (Milan, Italy). All the other chemicals were of analytical grade. RPMI 1640 cell culture medium, foetal calf serum (FCS), and phosphate-buffered saline were obtained from Celbio (Milan, Italy).

**Cell lines and culture conditions**

The human auranofin-sensitive parental ovarian cancer A2780 cell line was a gift of Prof. Kevin Scanlon (Keck Graduate Institute, CA, U.S.A). The auranofin-resistant cell subline (A2780/AF-R) was established from the parental sensitive cell line as described in the following paragraph. Cell lines were maintained in RPMI-1640 supplemented with 10% FCS and antibiotics (penicillin, 100 U/ml; streptomycin, 100 μg/ml) at 37°C in a 5% CO₂ humidified atmosphere and subcultured twice weekly.

**Development of resistance to auranofin**

A2780/AF-R cells were obtained by a continuous exposure of the parental sensitive A2780 cells to stepwise increasing auranofin concentrations. Initially, parental sensitive cells were grown in standard medium containing a low (sublethal) concentration of auranofin (100 nM). After 3 or 4 passages in this growth condition, auranofin concentration was increased in a stepwise manner up to 6 times until a 7 μM final concentration. This concentration level was achieved in an 8-month selection period.

**Cytotoxicity and drug resistance reversal assays**

The growth inhibitory effects of auranofin as well as of other six gold compounds and selected cytotoxic drugs against A2780/AF-R cells were determined by the SRB assay [66] to assess the degree of acquired resistance to auranofin and the potential occurrence of cross-resistance or collateral sensitivity to other drugs. Also, the potential modulation
of resistance to auranofin by verapamil, a calcium channel blocker capable of reversing the classical multidrug resistance phenotype, was determined by the same assay.

Exponentially growing cells were seeded in 96-well plates in RPMI 1640 supplemented with 10% FCS at a plating density of 4x10^4 cells/well.

After 24 hours, A2780 and A2780/AF-R cells were exposed to increasing concentrations of gold compounds or other drugs (cisplatin, carboplatin, oxaliplatin, melphalan, vinblastine, doxorubicin, paclitaxel, docetaxel and etoposide). Concentrations ranged from 1 nM to 100 μM and each concentration was tested in triplicate.

To assess the reversal of resistance to auranofin by verapamil, cells were pre-treated with this drug 15 min before auranofin exposure and co-exposed to verapamil during auranofin exposure. Concentrations of verapamil used (i.e. 5, 10, 20 μM) were not cytotoxic (lower than IC_{50}).

In all cases, after 72-hour drug exposure, cells were fixed with 10% trichloroacetic acid and stained with 0.4% SRB in 1% acetic acid. The SRB fixed to the cells was dissolved in 10 mM Tris-HCL and absorbance was read on an automated plate reader at a wavelength of 540 nm. The IC_{50} drug concentration resulting in a 50% reduction in the net protein content (as measured by SRB staining) in drug treated cells as compared to untreated control cells was determined. All the reported IC_{50} values represent the mean of at least three independent experiments.

The degree of acquired resistance to auranofin in A2780/AF-R cells was calculated as the ratio between IC_{50} values of A2780/AF-R and the IC_{50} value of the parental cell line (resistance index, RI).

The degree of cross-resistance to the other gold compounds or cytotoxic agents tested in A2780/AF-R cells was calculated as the ratio between IC_{50} values of A2780/AF-R and those of the parental cell line (cross-resistance index, CRI).

In the experiments of auranofin resistance reversal, the reversal fold (RF) values indicating the potency of reversal were calculated by dividing IC_{50} of auranofin alone by IC_{50} of auranofin in combination with verapamil.

### Determination of cellular gold accumulation

A2780/AF-R and parental A2780 cells were seeded in duplicate in 60 mm² Petri dishes in RPMI 1640 supplemented with 10% FCS at plating densities of 2x10^6 cells/dish following a 7-day culture period in drug-free medium.

After 24 hours, auranofin was added at high concentration (10 μM), then cells were incubated for 0, 2.5, 5, 10, 20, 40, 60, 80, 120, 240, and 480 min. The cell monolayers were washed 3 times with PBS and, after trypsinization, cells were pelleted, counted and then lysed by cell lysis buffer.

The gold content was determined following a previously published protocol [67] with some slight modifications. Each sample of pellet was recovered in a PE vial and digested in a thermo-reactor at 80°C for 8 h with 1.0 mL of HNO₃ 69.5% suprapure grade. After digestion, samples were diluted exactly to 6 mL with ultrapure water (≤18 MΩ). The determination of gold content in these solutions was performed in duplicate by a Varian 720-ES Inductively Coupled Plasma Atomic Emission Spectrometer (ICP-AES). The calibration curve of gold was obtained using known concentrations of a gold ICP standard solution purchased by Sigma-Aldrich. Moreover, each sample was spiked with 1 ppm of Ge used as an internal standard. The wavelengths used for Au determination were 242.795 and 267.595 nm whereas for Ge the line at 209.426 nm was used. The operating conditions were optimized to obtain maximum signal intensity and, between each sample, a rinse solution containing 1.0 mL of HNO₃ 69.5% suprapure grade and 5.0 mL of ultrapure water was used in order to avoid any “memory effect”.

The cellular gold content was calculated as the mean of two independent determinations and referred as total pmol Au/10⁶ cells. The area under the curve (AUC) of intracellular gold content was calculated by Graph Pad Prism Software (Inc., La Jolla, CA).

### Gene expression analysis

Overall, we analysed the expression of 24 mRNA genes involved in cellular transport and/or trafficking pathways. Genes were candidate on the basis of their known role in cell influx and/or efflux of metals (e.g. copper), metal-based anticancer drugs (e.g. platinum drugs), and more in general in tumour drug resistance. According to such criteria we evaluated the gene expression of 8 transporters belonging to the solute carrier family (SLC22A1, SLC22A2, SLC22A3, SLC31A1, SLC31A2, SLCO1B1, SLC01B3 and SLC47A1), 5 ATP-binding cassette transporters (ABCB1, ABCC1, ABCC2, ABCC3, ABCG2), 2 copper transporter ATPases (ATP7A, ATP7B), one copper chaperone (ATOX1), and 3 isoforms of Na⁺/K⁺ ATPase (ATP1A1, ATP1A2, ATP1A3). In addition, we analysed the mRNA expression of 4 clathrin isoforms (CLTA, CLTB, CLTC, CLTD), that are physiologically involved in mechanisms of internalization (e.g. endocytosis), and of PI3KCA gene that plays a key role in the signalling cascade associated with macropinocytosis. To identify genes with biologically significant expression changes, a 3-fold change was considered as an arbitrary cut-off [68].

### RNA preparation and amplification

Total RNA was isolated from A2780 and A2780/AF-R cell lines as previously described using a NucleoSpin® RNA Protein Kit (Macherey-Nagel, Germany) according to instruction’s manual. The RNA was quantified by Qubit™ 3.0 Fluorometer (Invitrogen, USA). 500ng of total RNA
were retro-transcribed using iScript (Bio-Rad, USA) and amplified with specific primers listed in Table 4. All primers were purchased from IDT (IDT, Germany). PCR amplification was carried out by means SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad, USA) according to manual instruction using the RotorGene 3000 Instrument (Qiagen Germany). Ribosomal 18s rRNA was used as the normalizer. Quantitative PCR was performed using the following procedure: 98°C for 2 min, 40 cycles of 98°C for 5 sec, 60°C for 10 sec. The program was set to reveal the melting curve of each amplicon from 60°C to 95°C with a read every 0.5°C.

**Western blot analysis**

60 µg of total proteins were separated by NuPAGE 12% Bis-Tris Gel and electroblotted (Turbo-Blot apparatus; Bio-Rad, USA) onto nitrocellulose membranes (Bio-Rad, USA) according to instruction’s manual. The following antibodies were used: SLC22A1, SLC47A1, ABCB1 and β-Actin (GeneTex, USA). The membranes were incubated overnight at 4°C. After incubation membranes were washed with TPBS and incubated 1 h in TPBS/5% milk containing the corresponding peroxidase-conjugated secondary antibody (1:2000) (Bio-Rad, USA). ECL (Bio-Rad, USA) was used to visualize the peroxidase-coated bands by means of ChemiDoc MP Imaging System (Bio-Rad, USA). Densitometric analysis was performed by Quantity One software (Bio-Rad, USA).

**Glutathione assay**

Glutathione content in A2780/AF-R and A2780 cells was determined by a spectrophotometric method. Briefly,
cells were seeded in 60 mm² Petri dishes at a plating density of 1x10⁶ cells/well and incubated for 48 h. Cells were harvested and counted, the levels of intracellular total glutathione (GSH + GSSG) and of the reduced glutathione form (GSH) were measured using ApoGSH™ Glutathione Colorimetric Detection Kit (BioVision, California, USA). Serial dilutions of GSH + GSSG and GSH were used to generate corresponding standard curves. GSH + GSSG and GSH concentrations were expressed as μg/10⁶ cells.

**Thioredoxin reductase activity**

Thioredoxin reductase activity was determined spectrophotometrically in cell extracts by the Thioredoxin Reductase Assay Kit (Sigma-Aldrich, St. Louis, MO). A2780 and A2780/AF-R cells were seeded in 100 mm² Petri dishes at a plating density of 2x10⁶ cells/well and incubated for 48 h. Cells were harvested, counted and washed with PBS. Samples were lysed with a 500 μl CellLytic Extraction Reagent (Sigma-Aldrich, St. Louis, MO) containing 50 μl of a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO). After 15 min of incubation on a shaker, lysates were centrifuged at 12,000 g for 15 min to pellet cell debris and the obtained supernatants were tested for enzyme activities. Enzymatic activity was assessed by measuring the absorbance at 412 nm using a microplate reader. The Bradford Reagent (Sigma-Aldrich, St. Louis, MO) was used to determine protein concentrations. Results are the mean of three independent experiments.

**Statistical analysis**

t-Tests were used for pairwise comparisons. P values <0.05 were considered statistically significant. All data were analysed using Graph Pad Prism version 5 (Graph Pad Prism Software Inc., La Jolla, CA).

**Author contributions**

I.L. established the resistant cell line, performed the experiments of cellular biology and the analysis of data with the participation of G.P. and prepared all the figures; she also drafted the manuscript together with S.N. and E.M.;
A.L. performed the experiments of molecular biology and the analysis of data together with C.N. and P.P.; A.P. and L.Ma performed the determination of cellular gold accumulation and the analysis of respective data; L.Me., E.M. and S.N. conceived the study, designed and interpreted the experiments. E.M. and S.N. also drafted the manuscript. All authors approved the final version of the manuscript.

**CONFLICTS OF INTEREST**

The authors declare no competing financial interests

**FUNDING**

This study was supported by contributions of Associazione Italiana per la Ricerca sul Cancro (AIRC-IG16049), Milan and Istituto Toscano Tumori (Messori-ITT-2015) (to L. Messori), Associazione Italiana per la Ricerca sul Cancro (IG no. 15565), Milan, Ente Cassa di Risparmio di Firenze (no. 2014/0706), Florence and Associazione Giacomo Onlus, Castiglioncello (to E Mini) and Ente Cassa di Risparmio di Firenze (no. 2014/0969), Florence (to S Nobili). LM thanks Prof. Rainer Schobert (Uni Bayreuth) for helpful suggestions.

**REFERENCES**

1. Bernhard GC. Auranofin therapy in rheumatoid arthritis. J Lab Clin Med. 1982; 100: 167-177.
2. Messori L, Marcon G. Gold complexes in the treatment of rheumatoid arthritis. Met Ions Biol Syst. 2004; 41: 279-304.
3. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008; 16: 112-25.
4. Simon TM, Kunishima DH, Vibert GJ, Lorber A. Inhibitory effects of a new oral gold compound on HeLa cells. Cancer. 1979; 44: 1965-1975.
5. Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K, Crooke ST. Evaluation of the *in vivo* antitumor activity and *in vitro* cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985; 45: 32-39.
6. Pessetto ZY, Chen B, Alturkmani H, Hyter S, Flynn CA, Baltezor M, Ma Y, Rosenthal HG, Neville KA, Weir SJ, Butte AJ, Godwin AK. In silico and *in vitro* drug screening identifies new therapeutic approaches for Ewing sarcoma. Oncotarget. 2017; 8: 4079-4095. https://doi.org/10.18632/oncotarget.13385.
7. Celegato M, Borgeshe C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, Spina M, Colombatti A, Aldinucci D. Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. Blood. 2015; 126: 1394-1397.
8. ClinicalTrials.gov - U.S. National Institutes of Health - www.clinicaltrials.org (last accessed August 2017).
9. Jenks S. New NIH center broadens scope of translational research. J Natl Cancer Inst. 2012; 104: 728-731.
10. Weir SJ, DeGennaro LJ, Austin CP. Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. Cancer Res. 2012; 72: 1055-1058.
11. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013; 12: 1299-1309.
12. Nobili S, Mini E, Landini I, Gabbiani C, Casini A, Messori L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med Res Rev. 2010; 30: 550-580.
13. Madeira JM, Gibson DL, Kean WF, Klegeris A. The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology. 2012; 20: 297-306.

14. Roder C, Thomson MJ. Auranofin: repurposing an old drug for a golden new age. Drugs RD. 2015; 15: 13-20.

15. Allauden H, Snyder RM, Whitman MH, Crooke ST. Effects of coordinated gold compounds on in vitro and in situ DNA replication. Biochem Pharmacol. 1985; 34: 3243-3250.

16. Soncini FC, Checha SK. Gold. Chapter 20, in “Binding, Transport and Storage of Metal Ions in Biological Cells” (eds: W. Maret, A. Wedd), The Royal Society of Chemistry, 2014; 553-593.

17. Liu W, Gust R. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs. Chem Soc Rev. 2013; 42: 755-773.

18. Cox AG, Brown KK, Armer ES, Hampton MB. The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol. 2008; 76: 1097-1109.

19. You BR, Park WH. Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion. Oncol Rep. 2016; 35: 546-551.

20. Rigobello MP, Messori L, Marcon G, Agostina Cinella M, Bragadin M, Folda A, Scutari G, Bindoli A. Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem. 2004; 98: 1634-1641.

21. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K. Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem. 1998; 273: 20096-2101.

22. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med. 2007; 42: 872-881.

23. Talbot S, Nelson R, Self WT. Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukemia. Br J Pharmacol. 2008; 154: 940-948.

24. Micale N, Schirmeister T, Ettari R, Cinella MA, Maiore L, Serratrice M, Gabbiani C, Massai L, Messori L. Selected cytotoxic gold compounds cause significant inhibition of 20S proteasome catalytic activities. J Inorg Biochem. 2014; 141: 79-82.

25. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, Liu S, Song W, Lu X, Lan X, Chen X, Yi S, Xu L, et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinating enzyme and inhibits tumor growth. Oncotarget. 2014; 5: 5453-5471. https://doi.org/10.18632/oncotarget.2113.

26. Huang H, Liao Y, Liu N, Hua X, Cai J, Yang C, Long H, Zhao C, Chen X, Lan X, Zang D, Wu J, Li X, et al. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget. 2016; 7: 2796-2808. https://doi.org/10.18632/oncotarget.6425.

27. Glennás A, Rugstad HE. Acquired resistance to auranofin in cultured human cells. Scand J Rheumatol. 1985; 14: 230-238.

28. Butt TR, Sternberg EJ, Mirabelli CK, Crooke ST. Regulation of metallothionein gene expression in mammalian cells by gold compounds. Mol Pharmacol. 1986; 29: 204-210.

29. Holohos C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13: 714-726.

30. Spreckelmeyer S, Orvig C, Casini A. Cellular transport mechanisms of cytotoxic metalloids: an overview beyond cisplatin. Molecules. 2014; 19: 15584-15610.

31. Snyder RM, Mirabelli CK, Crooke ST. Cellular association, intracellular distribution, and efflux of auranofin via sequential ligand exchange reactions. Biochem Pharmacol. 1986; 35: 923-932.

32. Kaps L, Biersack B, Müller-Bunz H, Mahal K, Münzner J, Tacke M, Mueller T, Schobert R. Gold (I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. J Inorg Biochem. 2012; 106: 52-58.

33. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijsen RH, Wiemer EA. Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat. 2011; 14: 22-34.

34. Arnesano F, Losacco M, Natile G. Platinum. Chapter 15 in: Binding, Transport and Storage of Metal Ions in Biological Cells. RSC Metallobiology series. Royal Society of Chemistry. 2014; 429-460.

35. SLC-Table – Bioparadigms - http://slc.bioparadigms.org (last accessed March 2017).

36. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66: 8847-8857.

37. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008; 36: 2299-2306.

38. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G, Hagos Y. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009; 69: 1494-1501.
39. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006; 319: 879-886.

40. Kim H, Wu X, Lee J. SLC31 (CTR) family of copper transporters in health and disease. Mol Aspects Med. 2013; 34: 561-570.

41. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006; 70: 1390-1394.

42. Terada T, Inui K. Physiological and pharmacokinetic roles of H+/organic cation antiporters (MATE/SLC47A). Biochem Pharmacol. 2008; 75: 1689-1696.

43. Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther. 2013; 12: 1537-1544.

44. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem. 2008; 15: 1981-2039.

45. Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006; 7: 861-879.

46. Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012; 32: 1220-1262.

47. Schmidt C, Karge B, Misgeld R, Prokop A, Franke R, Brönnstrup M, Ott I. Gold (I) NHC complexes: antiproliferative activity, cellular uptake, inhibition of mammalian and bacterial thioredoxin reductases, and gram-positive directed antibacterial effects. Chemistry. 2017; 23: 1869-1880.

48. Ekblad L, Kjellström J, Johnsson A. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs. 2010; 21: 523-531.

49. Kühne A, Tsvetkov MV, Hagos Y, Lage H, Bureckhardt G, Brockmüller J. Influx and efflux transport as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol. 2009; 78: 45-53.

50. Chen Z, Shi T, Zhang L, Zhu P, Deng M, Huang C, Hu T, Jiang L, Li J. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. Cancer Lett. 2016; 370: 153-164.

51. Blauz A, Rychlik B. Drug-selected cell line panels for evaluation of the pharmacokinetic consequences of multidrug resistance proteins. J Pharmacol Toxicol Methods. 2017; 84: 57-65.

52. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 2002; 62: 6559-6565.

53. Komatsu M, Sumizawa T, Mutoh M, Chen ZS, Terada K, Furukawa T, Yang XL, Gao H, Miura N, Sugiyama T, Akiyama S. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res. 2000; 60: 1312-1316.

54. Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004; 10: 4661-4669.

55. Ahmed Z, Deyama Y, Yoshimura Y, Suzuki K. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+, K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B. Cancer Chemother Pharmacol. 2009; 63: 643-650.

56. Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, et al. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016; 7: 3548-3558. https://doi.org/10.18632/oncotarget.6516.

57. Yamada M, Tomida A, Yoshikawa H, Taketani Y, Tsuruo T. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Clin Cancer Res. 1996; 2: 427-432.

58. Rigobello MP, Gandin V, Folda A, Rundlöf AK, Fernandes AP, Bindoli A, Marzano C, Björnstedt M. Treatment of human cancer cells with selenite or tellurite in combination with auranofin enhances cell death due to redox shift. Free Radic Biol Med. 2004; 37: 710-721.

59. Sasada T, Nakamura H, Ueda S, Sato N, Kataoka Y, Gon Y, Takabayashi A, Syprou G, Holmgren A, Yodoi J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diaminedichloroplatinum (II). Free Radic Biol Med. 1999; 27: 504-514.

60. Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016; 106: 27-36.

61. Cinellu MA, Minghetti G, Pinna MV, Stocco S, Zucca A, Manassero M, Sansoni M, mu-OxO and alkoxo complexes of gold (III) with 6-alkyl-2',2'-bipiridines. Synthesis, characterization and X-ray structures. J Chem Soc Dalton Trans. 1998; 11: 1735-1741.

62. Cinellu MA, Maïore L, Manassero M, Casini A, Arca M, Fiebig HH, Kelter G, Michelucci E, Pieraccini G, Gabbiani C, Messori L, Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget. 2016; 7: 3548-3558. https://doi.org/10.18632/oncotarget.6516.

63. Marcon G, Carotti S, Coronello M, Messori L, Mini E, Orioli P, Mazzei T, Cinellu MA, Minghetti G. Gold (III) complex showing excellent antiproliferative properties. ACS Med Chem Lett. 2010; 1: 336-339.
complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J Med Chem. 2002; 45: 1672-1677.

64. Ronconi L, Aldinucci D, Dou QP, Fregona D. Latest insights into the anticancer activity of gold (III)-dithiocarbamato complexes. Anticancer Agents Med Chem. 2010; 10: 283-292.

65. Messori L, Marchetti L, Massai L, Scaletti F, Guerri A, Landini I, Nobili S, Perrone G, Mini E, Leoni P, Pasquali M, Gabbiani C. Chemistry and biology of two novel gold (I) carbene complexes as prospective anticancer agents. Inorg Chem. 2014; 53: 2396-2403.

66. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990; 82: 1107-1112.

67. Marzo T, Pillozzi S, Hrabina O, Kasparkova J, Brabec V, Arcangeli A, Bartoli G, Severi M, Lunghi A, Totti F, Gabbiani C, Quiroga AG, Messori L. cis-PtI2(NH3)2: a reappraisal. Dalton Trans. 2015; 44: 14896-14905.

68. AbuHammad S, Zihlif M. Gene expression alterations in doxorubicin resistant MCF7 breast cancer cell line. Genomics. 2013; 101: 213-220.